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Purpose: The authors examined whether olprinone, a phosphodiesterase type 3 inhibitor, or 
isoflurane, a volatile anesthetic, could protect the heart against myocardial infarction in type 2 
diabetic rats and whether the underlying mechanisms involve protein kinase C (PKC), mitochondrial 
ATP-sensitive potassium (m-KATP) channels, or the phosphatidylinositol 3-kinase (PI3K)-Akt 
pathway. 
Methods: All rats underwent 30 min of coronary artery occlusion followed by 2 h of reperfusion. 
Wistar rats received isoflurane or olprinone before ischemia with or without the PKC inhibitor 
chelerythrine (CHE), the m-KATP channel blocker 5-hydroxydecanoic acid (5HD), or the PI3K-Akt 
inhibitor LY294002 (LY). Goto-Kakizaki (GK) rats were randomly assigned to receive isoflurane or 
olprinone. In another group, GK rats received LY before the olprinone. 
Results: In the Wistar rats, both isoflurane (38 ± 11%) and olprinone (40 ± 11%) reduced infarct size 
as compared to the control (59 ± 8%). In the GK rats, olprinone (41 ± 9%) but not isoflurane (53 ± 
11%) reduced infarct size as compared to the GK control (58 ± 14%). The beneficial effects of 
olprinone were blocked by LY (58 ± 14%). In the Wistar rats, CHE, 5HD, and LY prevented 
isoflurane-induced reductions of infarct size. On the other hand, LY but not CHE or 5HD prevented 
olprinone-induced reductions of infarct size. 
Conclusions: Olprinone but not isoflurane protects the heart against myocardial infarction in type 2 
diabetic rats. The olprinone-induced cardioprotective effect is mediated by the PI3K-Akt pathway 
but not PKC or m-KATP channels. (245 words) 
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Large-scale clinical trials have shown that diabetic individuals are prone to developing 
ischemic heart disease [1]. In addition, a number of studies have shown that the cardioprotective 
effects of ischemic preconditioning (IPC) and anesthetic preconditioning (APC) are impaired in 
alloxan and/or streptozotocin-induced type 1 diabetic models [2-5]. Dysfunctional mitochondrial 
ATP-sensitive potassium (m-KATP) channels have been shown to occur in diabetic hearts and cause 
impairment of myocardial preconditioning [4, 6-9]. It is generally accepted that the m-KATP channel 
is an integral player in the signal transduction pathway of IPC [10, 11] and APC [12, 13], and the 
m-KATP channel is also known as a mediator that is closely related to protein kinase C (PKC) in 
cardioprotective mechanisms. Recent studies have demonstrated PKC to be upstream and 
downstream of the m-KATP channel opening [14, 15]. 
Phosphodiesterase type 3 inhibitor (PDE3-I) increases the intracellular cyclic adenosine 
monophosphate (cAMP) level [16] and exerts a positive inotropic effect, which is not changed by 
diabetes [17]. Sanada et al. showed that preischemic administration of PDE3-Is reduces myocardial 
infarction via activation of the cAMP/PKA pathway independent of PKC [18]. However, whether 
such PDE3-Is-induced reductions in myocardial infarct size are attenuated by diabetes and whether 
the mechanisms of such reductions involve m-KATP channels are still unknown.  
We used Goto-Kakizaki (GK) rats, which are a selectively inbred model of type 2 diabetes 
developed from the Wistar rat. Type 2 diabetes in this rat has many similarities to the human form of 
the disease [19, 20], and these rats have been used extensively as a type 2 diabetic research model 
[21]. They appear to be a more appropriate diabetic research model because worldwide the most 
common form of diabetes is type 2 diabetes, the prevalence of which is steadily increasing [22]. 
Recent studies showed that IPC is impaired in type 2 diabetic models [9, 23, and 24]. However, 
whether the reductions in myocardial infarct size produced by APC are similarly attenuated is 
unknown.  
 Tsang et al. showed that repeated IPC stimulus is necessary to achieve the threshold for 
cardioprotection and the critical level of Akt phosphorylation that protects the diabetic myocardium 
[23]. PKC, m-KATP channels, and the phosphatidylinositol 3-kinase (PI3K)-Akt pathway mediate 
isoflurane-induced preconditioning in the non-diabetic rat heart [25, 26]. We have previously 
demonstrated that cardioprotection induced by olprinone, a PDE3-I, involves PI3K-Akt in 
non-diabetic rat hearts [27]. Thus, the present study was carried out to clarify whether olprinone or 
isoflurane could protect the heart against myocardial infarction in GK rats and whether the 
underlying mechanisms involve PKC, m-KATP channels, or the PI3K-Akt pathway. 
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Materials and Methods 
All experimental procedures and protocols described in this study were approved by the 
Institutional Animal Care and Use Committee of the Nagasaki University School of Medicine. 
 
Drugs 
Olprinone was purchased from Eisai (Tokyo, Japan). Isoflurane was purchased from 
Abbott Japan (Tokyo, Japan). Chelerythrine (CHE), sodium 5-hydroxydecanoic acid (5-HD), 
LY294002 (LY), patent blue dye, and 2,3,5-triphenyltetrazolium chloride (TTC) were purchased 
from Sigma (St. Louis, MO, USA).  
 
General Preparation 
Male Wistar rats weighing between 270 and 440 g and male GK rats weighing between 
260 and 400 g were anesthetized with sodium pentobarbital (a 50 mg/kg intraperitoneal bolus 
followed by an intravenous infusion of 10-20 mg/kg/h). The rats were adequately sedated to ensure 
that pedal and palpebral reflexes were absent throughout the experimental protocol. Catheters were 
inserted into the right jugular vein and the right carotid artery for fluid or drug administration and 
measurement of arterial blood pressure, respectively. After a tracheotomy had been performed, the 
trachea was intubated with a cannula connected to a small animal ventilator (model SAR-830 CWE, 
PA, USA), and the lungs were ventilated with pure oxygen. Arterial blood gas pH was maintained 
within a physiological range by adjusting the respiratory rate and tidal volume throughout the 
experiment. A left thoracotomy was performed in the fifth intercostal space, and the pericardium was 
opened. A 7-0 prolene ligature was placed around the proximal left anterior descending coronary 
artery (LAD) and vein in the area immediately below the left atrial appendage. The ends of the 
suture were threaded through a small plastic tube to form a snare for reversible LAD occlusion. 
Coronary artery occlusion was produced by clamping the snare onto the epicardial surface of the 
heart and was confirmed by the appearance of epicardial cyanosis. Reperfusion was achieved by 
loosening the snare and was verified by observing an epicardial hyperemic response. Hemodynamics 
were continuously monitored with a transducer (blood pressure monitor link sck-9082; Becton 
Dickinson, Tokyo, Japan) and an AP-641G blood pressure amplifier (Nihon-Kohden, Tokyo, Japan) 
and shown on a polygraph system (Nihon-Kohden). 
 
Experimental Protocol  
The experimental design used in the current investigation is illustrated in Figure 1. All rats 
underwent 30 min of coronary artery occlusion followed by 2 h of reperfusion.  
 4
The Wistar rats were randomly assigned to one of 12 groups. In 3 of these groups, the rats 
received saline (control), a 1.0% end-tidal concentration of isoflurane for 30min starting at 45 min 
before LAD occlusion, or an olprinone (10 μg/kg) i.v. bolus at 45 min before the LAD occlusion. In 
other the nine groups, the rats received a PKC inhibitor, CHE (5 mg/kg); an m-KATP channel blocker, 
5-HD (10 mg/kg); or a PI3K-Akt inhibitor, LY (0.3 mg/kg) i.v. bolus at 50 min before the LAD 
occlusion followed by saline, isoflurane, or olprinone.  
The GK rats were randomly assigned to one of 4 groups. In 3 of these groups, the rats 
received saline (control), isoflurane, or olprinone at the same time as the Wistar rat groups. In 
another group, the GK rats received an LY (0.3 mg/kg) i.v. bolus at 50 min before the LAD 
occlusion followed by olprinone. 
The doses of CHE [25], 5-HD [25], and LY [28] were set on the basis of a previous study. 
Isoflurane was administered via a vaporizer (ISOTEC3, Ohmeda, Steeton, UK). The end-tidal 
concentrations of isoflurane were measured using an infrared gas analyzer that was calibrated with 
known standards before and during experimentation. Following discontinuation of the volatile 
anesthetic, the end-tidal concentrations of isoflurane decreased to zero before the LAD occlusion. 
 
Blood Glucose Measurement 
Blood samples were collected to measure blood glucose in the Wistar rat control group and 
each GK rat group. The blood glucose level was determined by the glucose oxidase method using a 
Glutest sensor and Glutest Ace (Sanwa Kagaku Kenkyusho, Nagoya, Japan). Samples were taken 
before ischemia, just after starting reperfusion, and 2 h after starting reperfusion. 
 
Determination of Infarct Size 
Myocardial infarct size was measured as previously described [25]. Briefly, at the end of 
each experiment, the LAD was reoccluded, and patent blue dye was administered intravenously to 
stain the normal region of the left ventricle (LV), and the heart was rapidly excised. LV tissue was 
isolated and cut into approximately 10 cross-sectional pieces of equal thickness. The nonstained LV 
area at risk (AAR) was separated from surrounding blue-stained LV normal zone, and both regions 
were separately incubated at 37°C for 15 min in 1% TTC in 0.1 M phosphate buffer adjusted to pH 
7.4. The tissues were fixed overnight in 10% formaldehyde. AAR and blue-stained LV normal zone 
region were weighed for determination AAR / LV. TTC stains living tissue a deep red color, but 
necrotic tissue is TTC-negative and appears white within the AAR slices. Each slice was scanned at 
1200 dpi with a commercial scanner (Canoscan LiDE 60; Canon, Japan), and infarcted and 
noninfarcted areas were measured using an image analysis program. Myocardial infarct size was 
 5
expressed as a percentage of the AAR. 
 
Statistical Analysis 
Statistical analysis of hemodynamic data and blood glucose concentrations within and 
between groups was performed with analysis of variance for repeated measures followed by 
Dunnett’s test. Inter-group differences in body weight, age, LV weight, AAR weight, the ratio of 
AAR to LV, and the ratio of infarct size to AAR were analyzed using one-way analysis of variance 
followed by the Student-Newman-Keuls test. Statistical significance was defined as P < 0.05. All 
values were expressed as mean ± SD. Statistical analysis was performed using SPSS 15.0 software 




There were no significant differences in body weight or age among the groups. 
One hundred and seventy-five rats were instrumented to obtain 157 successful myocardial infarct 
size experiments. Nine rats were excluded as a result of technical difficulties with the experimental 
preparation. Malignant ventricular arrhythmias developed in nine other rats before completion of the 
experiment, and these rats were excluded from further analysis. 
 
Hemodynamics 
Mean arterial pressure (MAP) decreased in the CHE-treated Wistar rat group and GK 
control groups during reperfusion as compared to baseline, but no significant differences in MAP 
were observed under baseline conditions, before or during LAD occlusion or during reperfusion as 
compared with Wistar control group (Table 1).    
 
Infarct Size 
LV weight, AAR weight, and the ratio of AAR to total LV mass were similar among the 
groups (Table 2). In the Wistar rats, both isoflurane (38 ± 11%) and olprinone (40 ± 11%) reduced 
infarct size as compared to the control (59 ± 8%) (Fig. 2). In the GK rats, olprinone (41 ± 9%) but 
not isoflurane (53 ± 11%) reduced infarct size compared to the GK control (58 ± 14%). The 
beneficial effect of olprinone was blocked by LY (58 ± 14%) (Fig. 2). In the Wistar rats, CHE (56 ± 
10%), 5-HD (60 ± 10%), or LY (52 ± 12%) alone did not affect infarct size, but each of these 
inhibitors prevented the isoflurane-induced reduction of infarct size (51 ± 10%, 58 ± 9%, 54 ± 16%, 
respectively) (fig. 3). On the other hand, LY (54 ± 17%) but not CHE (42 ± 8%) or 5-HD (40 ± 11%) 
prevented the olprinone-induced reduction of infarct size (fig. 3).  
 
Blood Glucose Measurement 
The Wistar rats had normal concentrations of blood glucose at the baseline and had 
increased concentrations during coronary occlusion and reperfusion (table 3). The GK rats had 
abnormally high concentrations of blood glucose at the baseline and further increased concentrations 
during coronary occlusion and reperfusion. There were no significant differences in blood glucose 
concentration among the GK rat groups at any measured point. 
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Discussion 
 The major results of the current study are that olprinone protects both diabetic and 
non-diabetic hearts against ischemia-reperfusion injury, however, a 1.0% end-tidal concentration of 
isoflurane exerts a cardioprotective effect in non-diabetic hearts but not in type 2 diabetic hearts. 
Isoflurane-induced preconditioning in non-diabetic hearts is dependent on PKC, m-KATP channels, 
and PI3K-Akt, whereas olprinone-induced cardioprotection is mediated by PI3K-Akt independently 
of PKC and m-KATP channels. 
The present results show that isoflurane-induced preconditioning is attenuated in type 2 
diabetic rat hearts, confirming previous reports. Tanaka et al. showed that isoflurane-induced 
preconditioning is impaired in alloxan and streptozotocin-induced type 1 diabetic dogs and infarct 
size is directly related to blood glucose concentration [5]. Hyperglycemia alone, independent of 
diabetes, has also been shown to prevent isoflurane-induced preconditioning [29]. The present 
results demonstrate that in contrast to isoflurane, olprinone protects hearts against 
ischemia-reperfusion injury in type 2 diabetic rats to the same extent as in non-diabetic rats and that 
its protective effect is reversed by PI3K-Akt inhibition. PDEI induces cardioprotection through the 
elevation of the level of cAMP and PKA activation independent of PKC [30]. This transient 
pre-ischemic activation of PKA inhibits Rho-kinase [18]. The Rho-kinase inhibition activates the 
phosphorylation of Akt [31]. Our previous study showed that the activation of the PI3K-Akt pathway 
plays an important role in olprinone-induced cardioprotection [27]. It is likely that olprinone-induced 
Akt phosphorylation is preserved even in the diabetic myocardium. Tsang et al. reported that three 
cycles of IPC but not less reduced infarction in GK rats and that the effect was commensurate with 
significant Akt phosphorylation after three cycles of IPC [23]. They suggested that repeated IPC 
stimuli are needed to achieve the threshold for cardioprotection and a critical level of Akt 
phosphorylation is necessary to protect the diabetic myocardium. Thus, the effect of olprinone is 
comparable to the effects of repeated IPC stimuli in terms of Akt phosphorylation. 
PKC, m-KATP channels, and the phosphatidylinositol 3-kinase (PI3K)-Akt pathway 
mediate IPC and isoflurane-induced preconditioning [25, 26, and 32]. The present results also show 
that the PKC inhibitor CHE, the m-KATP channel blocker 5-HD, and the PI3K-Akt inhibitor LY, 
prevent isoflurane-induced reductions of infarct size in non-diabetic hearts. Furthermore, our results 
demonstrate for the first time that olprinone-induced cardioprotection is mediated by PI3K-Akt 
independent of PKC and m-KATP channels. Kersten et al. showed that the preconditioning evoked by 
the m-KATP channel opener, diazoxide, is blocked by diabetes and hyperglycemia, and the authors 
assumed that the blockage of m-KATP channels is the underlying mechanism of the lack of protection 
induced by volatile anesthetics in type 1 diabetics and acutely hyperglycemic animals [6]. Thus, it is 
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likely that olprinone-induced cardioprotection is mediated by a pathway independent of m-KATP 
channels and that this pathway is not attenuated by diabetes. Based on these results, new 
cardioprotective strategies that are independent of the m-KATP pathway would be effective for 
diabetic patients. 
The dose of olprinone was set on the basis of the clinical loading dose and our preliminary 
study, which showed that pretreatment with 10 μg/kg but not 3 μg/kg olprinone reduces infarct size 
(data not shown). Previous reports have demonstrated that lower but not higher concentrations of 
isoflurane-induced preconditioning are attenuated by diabetes and hyperglycemia and suggested that 
isoflurane stimulates but glucose inhibits m-KATP channel activity [5, 29]. In the present study, a 
1.0% end-tidal concentration of isoflurane exerted a cardioprotective effect in non-diabetic but not in 
type 2 diabetic hearts. The preischemic inhalation of a 1.0% end-tidal concentration of isoflurane 
and pretreatment with 10 μg/kg olprinone produced similar reductions in infarct size, suggesting that 
this concentration of isoflurane was appropriate for our experimental model. 
There was no difference in infarct size between the Wistar rat and GK rat control groups. It 
is unclear as to whether hearts from diabetic animal models are more sensitive or less sensitive to 
ischemia reperfusion injury. It was reported that hearts from type-2 diabetic rats suffer from larger 
infarct sizes after ischemia reperfusion injury than those from non-diabetic rats [9], whereas Tsang et 
al. [23] and Kristiansen et al. [24] reported smaller infarct sizes in diabetic hearts compared with 
non-diabetic hearts after ischemia-reperfusion. In the majority of human studies, both type 1 and 
type 2 diabetes increased the susceptibility of the heart to ischemia-reperfusion injury as shown by 
the worse outcome of diabetic patients after acute coronary syndromes [33]. In animal studies, 
differences in protocol or species might have caused the discrepancies in the results. 
In the CHE-treated Wistar rat group and GK control groups, MAP was significantly 
reduced by the end of reperfusion as compared to baseline. Decrease in MAP during reperfusion 
period probably due to the pump function reduction, so the possibility of affecting infarct size could 
not be denied. However, no significant differences in MAP were observed under baseline conditions, 
before or during LAD occlusion or during reperfusion as compared with Wistar control group. And 
Sato et al. [34] reported that coronary autoregulation was observed in the pressure range 50–100 
mmHg in Wistar rats. We also evaluated the relationship between MAP at the end of reperfusion and 
infarct size/AAR with linear regression analysis, and no correlation was found (r = 0.15, P = 0.08). 
Thus it is likely that decrease in MAP in the CHE-treated Wistar rat group and GK control groups 
has little effect on infarct size in this study.  
In summary, the current investigation indicates that preischemic administration of 
olprinone exerts cardioprotective effects independent of m-KATP channels and PKC, and that these 
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protective effects are preserved in type 2 diabetic rats. 
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Fig. 1. A schematic illustration of the experimental protocols. WISTAR = Wistar rat; GK = 
Goto-Kakizaki rat; CON = control; ISO = isoflurane; OLP = olprinone; CHE = chelerythrine; 5HD = 
5-Hydroxydecanoic acid; LY = LY294002. 
 
Fig. 2. Myocardial infarct size expressed as a percentage of the left ventricular area at risk in Wistar 
or Goto-Kakizaki rats receiving saline, isoflurane, or olprinone. WISTAR = Wistar rat; GK = 
Goto-Kakizaki rat; CON = control; ISO = isoflurane; OLP = olprinone; LY = LY294002. Data are 
mean ± SD. F value obtained from these data was 7.627. *Significantly (P < 0.05) different from 
WISTAR CON. †Significantly (P < 0.05) different from GK CON. ‡Significantly (P < 0.05) 
different between GK OLP and GK OLP+LY. 
 
Fig. 3. Myocardial infarct size expressed as a percentage of the left ventricular area at risk in Wistar 
rats receiving saline, isoflurane, or olprinone in the presence or absence of each inhibitor. WISTAR 
= Wistar rat; CON = control; ISO = isoflurane; OLP = olprinone; CHE = chelerythrine; 5HD = 
5-Hydroxydecanoic acid; LY = LY294002. Data are mean ± SD. F value obtained from these data 
was 5.293. *Significantly (P < 0.05) different from WISTAR CON. †Significantly (P < 0.05) 
different from WISTAR ISO. ‡Significantly (P < 0.05) different from WISTAR OLP. 
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Table 1. Systemic Hemodynamics 






30 min 1 hr 2 hr 
MBP (mmHg)       
 WISTAR CON 117 ± 14 112 ± 9 103 ± 11 118 ± 16 119 ± 27 111 ± 34 
 WISTAR ISO 116 ± 19 87 ± 35∗ 111 ± 18 119 ± 15 131 ± 11 124 ± 15 
 WISTAR OLP 115 ± 13 98 ± 17∗ 105 ± 15 111 ± 18 113 ± 18 119 ± 19 
 WISTAR CHE 128 ± 18 127 ± 22 110 ± 17∗ 107 ± 28∗ 109 ± 15∗ 101 ± 16∗ 
 WISTAR 5HD 138± 9 136 ± 18 122 ± 32 119 ± 25 119 ± 13 100 ± 38 
 WISTAR LY 103 ± 26 102 ± 28 98 ± 30 93 ± 29 99 ± 21 94 ± 26 
 WISTAR ISO + CHE 120 ± 27 118 ± 14 119 ± 15 107 ± 26 110 ± 28 106 ± 28 
 WISTAR ISO + 5HD 130 ± 10 122 ± 15 116 ± 13 124 ± 25 126 ± 27 125 ± 28 
 WISTAR ISO + LY 117 ± 18 101 ± 25 116 ± 18 119 ± 20 128 ± 14 123± 20 
 WISTAR OLP + CHE 126 ± 14 125 ± 16 116 ± 17 115 ± 16 112 ± 19 117 ± 29 
 WISTAR OLP + 5HD 121 ± 19 125 ± 10 132 ± 19 128 ± 26 120 ± 30 119 ± 28 
 WISTAR OLP + LY 120 ± 17 130 ± 7 126 ± 9 120 ± 12 119 ± 24 120 ± 28 
 GK CON 109 ± 25 112 ± 24 117 ± 30 96 ± 11 91 ± 11 74 ± 25∗ 
 GK ISO 114 ± 27 110 ± 24 132 ± 24 123 ± 18 119 ± 18 113 ± 16 
 GK OLP 99 ± 22 107 ± 16 111 ± 16 103 ± 12 104 ± 14 94 ± 24 
 GK OLP + LY 107 ± 11 121 ± 11 109 ± 19 109 ± 13 113 ± 21 102 ± 24 
Data are mean ± SD. 
MAP = mean arterial pressure; WISTAR = Wistar rat; GK = Goto-Kakizaki rat; CON = control; ISO = 
isoflurane; OLP = olprinone; CHE = chelerythrine; 5HD = 5-Hydroxydecanoic acid; LY = LY294002. 
*Significantly (P < 0.05) different from baseline. 
Table 2. Left-Ventricular Area at Risk 
 
Number Area at Risk/Left Ventricle (%) 
WISTAR CON 13 58 ± 9 
WISTAR ISO 12 55 ± 5 
WISTAR OLP 11 60 ± 8 
WISTAR CHE 6 51 ± 6 
WISTAR 5HD 9 60 ± 10 
WISTAR LY 8 52 ± 12 
WISTAR ISO + CHE 9 49 ± 11 
WISTAR ISO + 5HD 8 58 ± 9 
WISTAR ISO + LY 9 53 ± 8 
WISTAR OLP + CHE 9 50 ± 8 
WISTAR OLP + 5HD 9 56 ± 5 
WISTAR OLP + LY 9 54 ± 6 
GK CON 12 55 ± 9 
GK ISO 8 52 ± 9 
GK OLP 8 54 ± 5 
GK OLP + LY 8 49 ± 7 
Data are mean ± SD. 
WISTAR = Wistar rat; GK = Goto-Kakizaki rat; CON = control; ISO = isoflurane; OLP = olprinone; CHE = 
chelerythrine; 5HD = 5-Hydroxydecanoic acid; LY = LY294002. 
 







WISTAR CON 114 ± 63 146 ± 69∗ 142 ± 96∗ 
GK ISO 311 ± 145† 441± 136∗† 445 ± 115∗† 
GK OLP 284 ± 83† 390 ± 147∗† 448 ± 137∗† 
GK OLP + LY 271 ± 100† 414 ± 77∗† 500 ± 89∗† 
GK CON 258 ± 45† 413 ± 92∗† 449 ± 135∗† 
Data are mean ± SD. 
WISTAR = Wistar rat; GK = Goto-Kakizaki rat; CON = control; ISO = isoflurane; OLP = olprinone; LY = 
LY294002. *Significantly (P < 0.05) different from baseline. †Significantly (P < 0.05) different from 
WISTAR CON. 
